Oral Treatments for Relapsing-remitting MS

March 2010
Internal Medicine Alert;3/15/2010 Supplement, p1
The article discusses the oral medications for relapsing-remitting multiple sclerosis (MS).


Related Articles

  • Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Lugaresi, A.; Caporale, C.; Farina, D.; Marzoli, F.; Bonanni, L.; Muraro, P. A.; De Luca, G.; Iarlori, C.; Gambi, D. // Neurological Sciences;Apr2001, Vol. 22 Issue 2, p209 

    We aimed to further assess the safety and efficacy of low-dose oral methotrexate (LDOM) treatment for chronic progressive MS (CPMS). We studied 20 CPMS patients, including 16 with secondary progressive MS who had shown disease progression in the previous year. The mean follow-up was 23 months....

  • Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Paisley, S; Beard, S; Hunn, A; Wight, J // Multiple Sclerosis (13524585);Aug2002, Vol. 8 Issue 4, p319 

    Spasticity is a common disabling feature of multiple sclerosis. A variety of drugs are in regular use as oral treatment, including baclofen, dantrolene, tizanidine, and diazepam. Published evidence of effectiveness is limited. Most trials are of small size, of short duration, and have not...

  • Oral Treatments for Relapsing-remitting MS. Elliott, William T. // Critical Care Alert;Mar2010 Pharmacology Watch, p1 

    The article focuses on the oral medications for the treatment of relapsing-remitting multiple sclerosis (MS).

  • First oral treatment provides choice for multiple sclerosis.  // British Journal of Hospital Medicine (17508460);May2011, Vol. 72 Issue 5, p249 

    The article reports that fingolimod 0.5 mg (Gilenya) is the first oral treatment that provides choice for people with highly active relapsing remitting multiple sclerosis.

  • Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis. Muir, Victoria J.; Plosker, Greg L. // CNS Drugs;2011, Vol. 25 Issue 3, p239 

    Cladribine, an immunosuppressant that selectively reduces peripheral lymphocyte levels, has potential as an oral therapy for relapsing-remitting multiple sclerosis. An oral (tablet) formulation is being investigated in clinical trials. In the large, well designed, phase III CLARITY trial,...

  • Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 3, p75 

    In this article, the author discusses a study on the treatment of relapsing-remitting multiple sclerosis (MS) using oral fingolimod. It stresses that the oral agents cladribine, fingolimod, laquinimod, and teriflunomide have demonstrated promising results in Phase II clinical trials and are...

  • Highlights on Dalfampridine - New Therapy in All Types of Multiple Sclerosis. Antochi, Florina // Romanian Journal of Medical Practice;2011, Vol. 6 Issue 3, p232 

    This article presents information on Ampyra or Dalfampridine extended release, a new drug used for the treatment of all types of multiple sclerosis. This drug is indicated as a treatment to improve walking of patients suffering from multiple sclerosis. It is an orally administered formulation of...

  • Emerging oral therapies for multiple sclerosis. Guthrie, Ellen Whipple // Pharmacy Today;Jun2009, Vol. 15 Issue 6, p31 

    The article offers information on an emerging therapies for multiple sclerosis (MS). Oral therapies for MS include cladribine, laquinimod, fingolimod and dimethyl fumarate. It notes that Cladribine is approved as an injectable agent for hairy cell leukemia. Fingolimod will help in circulating...

  • Oral therapy approved for multiple sclerosis. Traynor, Kate // American Journal of Health-System Pharmacy;5/1/2013, Vol. 70 Issue 9, p744 

    The article reports on the approval of dimethyl fumarate delayed-release oral capsules for the treatment of relapsing forms of multiple sclerosis. The capsules, manufactured by the U.S. biotechnology company Biogen Idec under the brand name Tecfidera, have been shown to lessen disease activity,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics